Entasis Therapeutics Revenue and Competitors

Boston, MA USA

Location

$199.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Entasis Therapeutics's estimated annual revenue is currently $10.4M per year.(i)
  • Entasis Therapeutics's estimated revenue per employee is $546,579
  • Entasis Therapeutics's total funding is $199.5M.

Employee Data

  • Entasis Therapeutics has 19 Employees.(i)
  • Entasis Therapeutics grew their employee count by -46% last year.

Entasis Therapeutics's People

NameTitleEmail/Phone
1
VP Clinical DevelopmentReveal Email/Phone
2
VP, DMPKReveal Email/Phone
3
VP, Head Global Regulatory Affairs and Pharmacovigilance OperationsReveal Email/Phone
4
Head API, Pharmaceutical SciencesReveal Email/Phone
5
Associate Director Process ChemistryReveal Email/Phone
6
Director, API Process DevelopmentReveal Email/Phone
7
Chief Development OfficerReveal Email/Phone
8
Associate DirectorReveal Email/Phone
9
Director, Clinical ScientistReveal Email/Phone
10
CFO/Chief Business OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Entasis Therapeutics?

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of novel clinical and preclinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases.

keywords:N/A

$199.5M

Total Funding

19

Number of Employees

$10.4M

Revenue (est)

-46%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Entasis Therapeutics News

2022-04-17 - Entasis Therapeutics Presents SUL-DUR Topline Data from ...

About Entasis Therapeutics Holdings Inc. Entasis is a late-stage clinical biopharmaceutical company focused on the discovery, development and...

2022-04-17 - Global Acinetobacter Infections Treatment Market 2022 ...

Global Acinetobacter Infections Treatment Market 2022 Valuable Growth Prospects Analysis by 2028 | Entasis Therapeutics, Roche,...

2022-04-13 - -$0.20 Earnings Per Share Expected for Entasis Therapeutics ...

-$0.20 Earnings Per Share Expected for Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) This Quarter. Posted by admin on Apr 13th, 2022.

2017-09-05 - Entasis Therapeutics Raises $31.9M Extension of Series B Financing

Entasis Therapeutics, a Waltham, Mass.-based leader in the discovery and development of anti-infective products, closed a $31.9m Series B-1 extension financing. The financing expansion adds Pivotal bioVenture Partners, Sofinnova Ventures and TPG Biotech to the original Series B funding round of ...

2016-04-04 - Entasis Therapeutics Completes $50M Series B Financing

Entasis Therapeutics, a Waltham, Mass.-based company focused on the discovery and development of anti-infective products, completed a $50m Series B financing. The round was led by Clarus with participation from Frazier Healthcare Partners, Novo A/S, and Eventide Funds, which joined founding inv ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.7M196%N/A
#2
$1.6M196%N/A
#3
$3.4M20-84%N/A
#4
$3.1M20-17%N/A
#5
$2M20-13%$58M